Panelists discuss how pharmacists actively engage in educating and coordinating with nurses, oncologists, and other health care providers by conducting in-service trainings, participating in multidisciplinary team meetings, and collaborating on the development and implementation of formularies, order sets, and treatment protocols to ensure optimal patient care in multiple myeloma management.
Trent Thiede, PharmD, president of Pharmacy Audit Assistance Service (PAAS) International, discussed how pharmacy teams can remain prepared for audits from pharmacy benefit managers (PBMs).
Melissa Zinszer, PharmD, CDCES, explores the multifaceted role of pharmacists and healthcare providers in managing behind-the-counter medications, addressing patient concerns, optimizing over-the-counter therapy, and ensuring safe, effective treatment through careful symptom assessment and consideration of drug interactions.
Melissa Zinszer, PharmD, CDCES, explores the multifaceted role of pharmacists and healthcare providers in managing behind-the-counter medications, addressing patient concerns, optimizing over-the-counter therapy, and ensuring safe, effective treatment through careful symptom assessment and consideration of drug interactions.
Erin Rexroth, associate director of marketing for NCPA, discussed how pharmacies can utilize marketing strategies to drive awareness and patient engagement.
Panelists discuss how pharmacists play a crucial role throughout the multiple myeloma patient journey, from diagnosis to treatment, by contributing to medication management, patient education, adverse effect monitoring, and the development and implementation of order sets and clinical pathways within electronic medical record systems, thereby enhancing treatment efficacy and patient safety.
Panelists discuss how subcutaneous (SC) administration of drugs like daratumumab offers advantages over intravenous (IV) administration in terms of reduced health care resource utilization, improved patient convenience, and potentially better treatment adherence, while also considering potential drawbacks such as injection site reactions and the need for proper training in SC administration techniques.
Carrie Koenigsfeld, PharmD, FAPhA, discusses how pharmacists can incorporate RSV vaccination education and recommendations into daily pharmacy workflows, including prescription pick-ups, consultations, and routine MTM sessions.
Judith Joseph, MD, MBA addressed ADHD misdiagnosis, symptoms, and effective treatments.
Nathan Vanderford, PhD, MBA speaks about barriers to cancer care access experienced by patients in rural communities.
Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.
Pharmacists are encouraged to leverage prescription drug monitoring programs connect patients to community-based resources to address the opioid crisis and pharmacy deserts.
Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.
Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.
Panelists discuss how recent phase 3 trial data from PERSEUS, IsKia, and GMMG HD7 are shaping their approach to induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, particularly focusing on the incorporation of CD38 antibodies into upfront treatment regimens and the potential shift from triplet to quadruplet therapies based on these pivotal trial findings.
Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to educate older adults with low health literacy.
Damage to a Baxter manufacturing plant in the aftermath of Hurricane Helene has led to significant IV fluid shortages throughout the country.
Stephanie White, PharmD, CSP, is presenting at the NCODA Fall Summit in Orlando, Florida.
Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.
Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.
Pharmacists are positioned to combat the opioid crisis through educating the public and advocating for policy changes to enable harm reduction strategies.
Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Two MUSC pharmacy technicians discuss how techs are pivotal in pharmacy, whether in the community or clinical setting, and how it is important to maintain high standard of care in a changing environment.
Simply stating a team member good job, whether it be within a group or in a 1-on-1 setting, 2 MUSC pharmacy technicians emphasize that recognition and encouragement go a long way.
Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.
Ilianette Miranda, RPh discusses her career-long efforts to integrate pharmacists into the health care system in Puerto Rico.
In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.
The president and CEO of Employers' Forum of Indiana says the pharmacists must be involved and engaged with employers to improve outcomes in health care.
